High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

1 Apr 2011

Discovery of potent class of anti-cancer compounds by Scripps Research and MIT scientists

Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.

8 Mar 2011

Researchers transform human embryonic stem cell into neuron that dies early in Alzheimer's disease

Northwestern Medicine researchers for the first time have transformed a human embryonic stem cell into a critical type of neuron that dies early in Alzheimer's disease and is a major cause of memory loss.

4 Mar 2011

Evotec partners with ChemBridge to expand high throughput screening collection

Evotec AG today announced that it has entered into a collaboration with ChemBridge to further enhance its screening library. This collaboration demonstrates Evotec's continued improvement to its industry leading hit identification platform.

15 Feb 2011

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

Akonni Biosystems, a molecular diagnostics (MDx) company that develops rapid, low-cost and highly scalable solutions for infectious disease testing, today announced it has signed a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

10 Feb 2011

First commercially available full length human MTOR protein with superior biological activity released

OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.

2 Feb 2011

University of California study may shed light on human ability to adapt hypoxia

In an important study that may shed light on human ability to adapt to hypoxia, or inadequate levels of oxygen, researchers at the University of California, San Diego School of Medicine have proven that the genome of flies exposed to long-term hypoxia are changed to permanently affect gene expression.

24 Jan 2011

Math may help assess how rapidly stem cells and cancer-causing cousins increase numbers

The difficult task of sorting and counting prized stem cells and their cancer-causing cousins has long frustrated scientists looking for new ways to help people who have progressive diseases.

21 Jan 2011

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer's disease and major psychiatric disorders.

18 Jan 2011

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.

6 Jan 2011

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

5 Jan 2011

AMRI, Genentech enter research and licensing collaboration

AMRI announced today a research and licensing agreement with Genentech, a member of the Roche Group, for a family of antibacterial compounds discovered from AMRI's proprietary research of its natural products sample collection.

5 Jan 2011

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010.

19 Nov 2010

New investigational drug improves lung function in CF patients

An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.

17 Nov 2010

Verastem closes $16 million Series A financing

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.

16 Nov 2010

Researchers develop human cell-based model of Rett syndrome

A groundbreaking study published Friday in the leading scientific journal, Cell, revealed that a team of investigators had successfully generated nerve cells using skin cells from four individuals with Rett syndrome. The study, funded in part by IRSF, was led by Dr. Alysson Muotri at the University of California, San Diego--a leading researcher in the stem cell field.

16 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Arrayit sells third advanced microarray manufacturing system to UT Southwestern

Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.

2 Nov 2010